Ghayas Issa
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ghayas Issa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:18 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06769490 · Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06629584 · Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Malignant Solid Tumors · principal investigator
- Ph1/Ph2NCT06284486 · A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06229912 · A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesM.D. Anderson Cancer Center · recruiting · Leukemia, HOX Gene · principal investigator
- Ph1/Ph2NCT05360160 · A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02286726 · CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 07:18 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J Med · 2024156 citationsRCR 21.1
- 58 citationsRCR 2.2
- The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.Am J Hematol · 202121 citationsRCR 1.4
- Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.Lancet Haematol · 202419 citationsRCR 2.6
- Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.Cancer · 202415 citationsRCR 2.1
- 14 citationsRCR 7.0
- Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.Cancer · 202410 citationsRCR 1.4
- A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.Am J Hematol · 202410 citationsRCR 1.2
- Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.Clin Lymphoma Myeloma Leuk · 2026